These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23716052)

  • 1. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.
    Lee HJ; Bergen PJ; Bulitta JB; Tsuji B; Forrest A; Nation RL; Li J
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3738-45. PubMed ID: 23716052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.
    Deris ZZ; Yu HH; Davis K; Soon RL; Jacob J; Ku CK; Poudyal A; Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Paterson DL; Velkov T; Li J; Nation RL
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5103-12. PubMed ID: 22802247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
    Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
    Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
    Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.
    Bian X; Liu X; Feng M; Bergen PJ; Li J; Chen Y; Zheng H; Song S; Zhang J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106271. PubMed ID: 33352235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
    Bae S; Kim MC; Park SJ; Kim HS; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6774-6779. PubMed ID: 27600048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.
    Peck KR; Kim MJ; Choi JY; Kim HS; Kang CI; Cho YK; Park DW; Lee HJ; Lee MS; Ko KS
    J Med Microbiol; 2012 Mar; 61(Pt 3):353-360. PubMed ID: 22016557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.
    Cheah SE; Li J; Tsuji BT; Forrest A; Bulitta JB; Nation RL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3921-33. PubMed ID: 27067324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii.
    Nordqvist H; Nilsson LE; Claesson C
    Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1845-1850. PubMed ID: 27510182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.
    Galani I; Orlandou K; Moraitou H; Petrikkos G; Souli M
    Int J Antimicrob Agents; 2014 Apr; 43(4):370-4. PubMed ID: 24560919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.
    Liang W; Liu XF; Huang J; Zhu DM; Li J; Zhang J
    BMC Infect Dis; 2011 Apr; 11():109. PubMed ID: 21521536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
    Pachón-Ibáñez ME; Docobo-Pérez F; López-Rojas R; Domínguez-Herrera J; Jiménez-Mejias ME; García-Curiel A; Pichardo C; Jiménez L; Pachón J
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1165-72. PubMed ID: 20047914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
    Liu X; Zhao M; Chen Y; Bian X; Li Y; Shi J; Zhang J
    Int J Antimicrob Agents; 2016 Nov; 48(5):559-563. PubMed ID: 27670371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.
    Tan CH; Li J; Nation RL
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3413-5. PubMed ID: 17620384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
    Cai X; Yang Z; Dai J; Chen K; Zhang L; Ni W; Wei C; Cui J
    Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii.
    Bai Y; Liu B; Wang T; Cai Y; Liang B; Wang R; Liu Y; Wang J
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1466-71. PubMed ID: 25534730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
    Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
    J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.